Erika Zanzarelli

Dr. Erika Zanzarelli

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Journal of Clinical Ultrasound
Verified
Journal Article
Closed access
LVLorenzo Vasciaveo
Lorenzo Vasciaveo
EZErika Zanzarelli
Erika Zanzarelli
FDFrancesco D'ANtonio
Francesco D'ANtonio

Felice SorrentinoFelice Sorrentino
Felice Sorrentino
LVLorenzo Vasciaveo
Lorenzo Vasciaveo
VFVincenzo De Feo
Vincenzo De Feo
EZErika Zanzarelli
Erika Zanzarelli
EGElvira Grandone
Elvira Grandone
LNLuigi Nappi
Luigi Nappi
Interstitial pregnancy (IP) accounts for 2% of all ectopic pregnancies and has a mortality rate of 2–2.5%. The diagnosis is made by a transvaginal ultrasound and the treatment can be medical or surgical. We report the case of a 36-year-old primigravida who was 6 + 5 weeks pregnant, diagnosed with interstitial pregnancy by ultrasound, who had a very high serum β-hCG level (31,298 mIU/mL) and wanted to preserve her fertility. The patient was treated with one dose of mifepristone and a double dose of methotrexate since the decrease in the β-hCG serum level was less than 15% after the first dose. At the beginning, medical therapy was effective, as no embryonal cardiac activity was detected and serum β-hCG levels decreased early, but on the 20th day of hospitalization, the patient underwent surgery for her clinical symptoms and the evidence of free fluid in the Douglas pouch at a transvaginal ultrasound exam. Our experience showed that medical treatment should be considered, especially in women wishing to preserve their fertility. Further studies are needed to establish a standardized protocol and maybe a clinical score that can be useful in predicting the patients in which medical therapy could be most successful.

9 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AMAnna Lucia Mastricci
Anna Lucia Mastricci
Felice SorrentinoFelice Sorrentino
Felice Sorrentino
EGElisa Giansiracusa
Elisa Giansiracusa
EZErika Zanzarelli
Erika Zanzarelli
GLGraziana Silvana De Lucia
Graziana Silvana De Lucia
LVLorenzo Vasciaveo
Lorenzo Vasciaveo
Background: Hodgkin lymphoma (HL) is a common malignancy among women of reproductive age. Some pregnancies occur during oncological treatments or diagnostic follow-ups, often involving contraindicated procedures. HL is fluorodeoxyglucose-avid; therefore, its staging is generally performed with 18F-FDG PET/CT, a diagnostic method contraindicated during pregnancy. Immune checkpoint inhibitors (ICIs), such as pembrolizumab, are innovative therapies for relapsed HL (rHL) with significant efficacy. However, ICIs can impair immune tolerance, potentially increasing immune-related adverse events. The PD-1/PD-L1 pathway, targeted by pembrolizumab, plays a critical role in maternal–fetal immune adaptation, raising concerns about its safety during pregnancy. Case Report: We report the case of a 36-year-old woman diagnosed with rHL who unknowingly became pregnant during treatment with pembrolizumab and 18F-FDG PET/CT scans. The pregnancy was diagnosed at 24 weeks, after five cycles of pembrolizumab during the first two trimesters and an 18F-FDG PET/CT scan in the first trimester. Following multidisciplinary counseling, the pregnancy was closely monitored, culminating in the delivery of a healthy male infant at 37.5 weeks. Conclusions: This case highlights a favorable maternal–fetal outcome despite exposure to pembrolizumab and 18F-FDG PET/CT during pregnancy. Given the limited data on such exposures, case reports like this are essential for improving counseling and management strategies. Further research and registries are crucial to provide robust evidence for clinical decision-making in these complex scenarios.

31 July 2024 in Journal of Clinical Ultrasound
Verified
Journal Article
Closed access
LVLorenzo Vasciaveo
Lorenzo Vasciaveo
AMA. L. Mastricci
A. L. Mastricci
GLG. De Lucia
G. De Lucia
EZErika Zanzarelli
Erika Zanzarelli
VFV. De Feo
V. De Feo
LNL. Nappi
L. Nappi

31 January 2023 in Journal of Clinical Ultrasound
Verified
Journal Article
Closed access
LVLorenzo Vasciaveo
Lorenzo Vasciaveo
EZErika Zanzarelli
Erika Zanzarelli
GLGraziana Silvana De Lucia
Graziana Silvana De Lucia
VFVincenzo De Feo
Vincenzo De Feo
AMAnna Lucia Mastricci
Anna Lucia Mastricci
LNLuigi Nappi
Luigi Nappi